HJ Science Co., Ltd.

Primary objective: To evaluate the safety and tolerability of multiple oral administrations of HJ197 capsules in patients with advanced hepatocellular carcinoma (HCC), and to determine the maximum tolerated dose (MTD) and the recommended dose for stage II (RP2D).

A single-arm, open-label phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and antitumor efficacy of HJ891 in the treatment of advanced solid tumors.

1) To quantitatively analyze the total radioactivity in excreta (urine and feces) after oral administration of [14C]HJ891 in healthy male subjects and determine the cumulative excretion rate and major excretion pathways of radioactivity in humans; 2) To investigate the distribution of total radioactivity in whole blood and plasma and the pharmacokinetics of total radioactivity in whole blood and plasma following a single oral administration of [14C]HJ891 in healthy male subjects; 3) To identify the major metabolites of [14C]HJ891 in the human body and determine the major biotransformation pathways and structures of the major metabolites.